Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gay

Showing results (371-380 of 392) with videos related to

Pageof 40
Sort By:
International Journal of Cancer|July 13, 2024
Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profilingJacqueline A Turner, Robert J Van Gulick, William A Robinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2024
YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic VulnerabilitiesC Allison Stewart, Lixia Diao, Yuanxin Xi, et al.
Cancer Cell|January 22, 2021
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilitiesCarl M Gay, C Allison Stewart, Elizabeth M Park, et al.
Cancers|December 11, 2025
MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung CancerHui Li, Lingzhi Hong, Pedro Rocha, et al.
JTO Clinical and Research Reports|February 15, 2024
Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From <i>EGFR</i>-Mutant NSCLC Informs Potential Therapeutic TargetsBingnan Zhang, Whitney Lewis, C Allison Stewart, et al.
Cancer Immunology Research|June 13, 2023
β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon CancerToshiyasu Suzuki, Anna Kilbey, Nuria Casa-Rodríguez, et al.
Nature Communications|January 5, 2021
A RAC-GEF network critical for early intestinal tumourigenesisK A Pickering, K Gilroy, J W Cassidy, et al.
Journal for Immunotherapy of Cancer|August 11, 2021
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancerMarcelo V Negrao, Ferdinandos Skoulidis, Meagan Montesion, et al.
The Oncologist|October 13, 2019
The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRAUmut Disel, Russell Madison, Kumar Abhishek, et al.
Nature Communications|February 8, 2023
Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancerLingzhi Hong, Muhammad Aminu, Shenduo Li, et al.
Pageof 40

Showing results (371-380 of 392) with videos related to

Sort By:
Pageof 40
International Journal of Cancer|July 13, 2024
Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profilingJacqueline A Turner, Robert J Van Gulick, William A Robinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2024
YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic VulnerabilitiesC Allison Stewart, Lixia Diao, Yuanxin Xi, et al.
Cancer Cell|January 22, 2021
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilitiesCarl M Gay, C Allison Stewart, Elizabeth M Park, et al.
Cancers|December 11, 2025
MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung CancerHui Li, Lingzhi Hong, Pedro Rocha, et al.
JTO Clinical and Research Reports|February 15, 2024
Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From <i>EGFR</i>-Mutant NSCLC Informs Potential Therapeutic TargetsBingnan Zhang, Whitney Lewis, C Allison Stewart, et al.
Cancer Immunology Research|June 13, 2023
β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon CancerToshiyasu Suzuki, Anna Kilbey, Nuria Casa-Rodríguez, et al.
Nature Communications|January 5, 2021
A RAC-GEF network critical for early intestinal tumourigenesisK A Pickering, K Gilroy, J W Cassidy, et al.
Journal for Immunotherapy of Cancer|August 11, 2021
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancerMarcelo V Negrao, Ferdinandos Skoulidis, Meagan Montesion, et al.
The Oncologist|October 13, 2019
The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRAUmut Disel, Russell Madison, Kumar Abhishek, et al.
Nature Communications|February 8, 2023
Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancerLingzhi Hong, Muhammad Aminu, Shenduo Li, et al.
Pageof 40